2019
Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts
Laird J, Lok B, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier J, Rudin C. Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts. Journal Of Thoracic Oncology 2019, 14: 1743-1752. PMID: 31195178, PMCID: PMC6764879, DOI: 10.1016/j.jtho.2019.05.032.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCell ProliferationFemaleFluorine RadioisotopesHumansLung NeoplasmsMiceMice, Inbred NODMice, SCIDPhthalazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPositron-Emission TomographyRadiopharmaceuticalsSmall Cell Lung CarcinomaTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsPatient-derived xenograftsPositron emission tomographicPARP inhibitorsTherapeutic efficacyTarget engagementPositron emission tomographic imagingDifferential therapeutic efficacyTumor radiotracer uptakeTumor growth inhibitionEnzyme-linked immunosorbentDose-dependent mannerFluorine-18Oral talazoparibMultiple dosesSingle dosesTotal tumorsPolymerase-1 (PARP-1) inhibitorsPET uptakeRadiotracer uptakeInhibitor of polyIndividual tumorsPET/Drug efficacyTalazoparib treatmentPromising therapeutics
2018
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
Laird J, Lok B, Ma J, Bell A, de Stanchina E, Poirier J, Rudin C. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clinical Cancer Research 2018, 24: 5143-5152. PMID: 29945991, PMCID: PMC6742772, DOI: 10.1158/1078-0432.ccr-18-0401.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalDisease Models, AnimalDNA Breaks, Double-StrandedDose-Response Relationship, DrugHumansPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsRadiation ToleranceRadiation, IonizingRadiation-Sensitizing AgentsSmall Cell Lung CarcinomaXenograft Model Antitumor AssaysConceptsSmall cell lung cancerSCLC cell linesClonogenic survival assaysCell linesPatient-derived xenograft modelsPARP inhibitionShort-term viability assaysDoses of veliparibCell lung cancerClin Cancer ResEfficacy of radiotherapyTumor growth inhibitionViability assaysAggressive malignancyLung cancerPDX modelsNovel therapiesSCLC cellsXenograft modelSingle agentPARP inhibitorsCancer ResTalazoparibSurvival assaysContribution of PARP